Is lamotrigine (Lamictal) or aripiprazole (Abilify) more effective for treating anxiety?

Neither Lamictal (lamotrigine) nor Abilify (aripiprazole) should be used as first-line treatment for primary anxiety disorders

For primary anxiety disorders, SSRIs (escitalopram, sertraline) are the established first-line treatments, not lamotrigine or aripiprazole 1. Neither medication has FDA approval for anxiety disorders, and the evidence supporting their use is limited to specific contexts.

Evidence Quality and Context

Lamotrigine (Lamictal)

• No FDA indication for anxiety disorders
• Recent guidelines explicitly state that lamotrigine augmentation is ineffective or potentially harmful for treatment-resistant OCD 2
• No randomized controlled trials exist for lamotrigine in primary anxiety disorders
• Its primary evidence base is for bipolar depression maintenance, not anxiety 3, 4

Aripiprazole (Abilify)

• No FDA indication for anxiety disorders 5
• FDA approval exists only for: schizophrenia, bipolar disorder, adjunctive treatment of major depression, and autism-related irritability
• Limited evidence from only two small open-label trials in anxiety disorders 6
• One small open-label study (n=23) showed potential benefit as augmentation in treatment-resistant GAD and panic disorder, but 13% discontinued due to side effects 7
• Retrospective data suggests possible benefit when augmenting SSRIs in treatment-resistant cases 8

Clinical Decision Algorithm

If treating primary anxiety disorder:

1. Start with SSRI monotherapy (escitalopram or sertraline) at adequate doses for 8-12 weeks 1
2. If inadequate response, switch to another SSRI or SNRI (venlafaxine) 1
3. If still treatment-resistant, consider aripiprazole augmentation (low doses: 2-15 mg/day) based on open-label evidence 7, 8
4. Do not use lamotrigine - evidence suggests it is ineffective 2

If treating bipolar depression with comorbid anxiety:

• Both medications have roles here: lamotrigine for maintenance 4, aripiprazole for acute treatment 3
• This is a different clinical scenario than primary anxiety disorders

Critical Caveats

• Aripiprazole carries FDA black box warning for increased mortality risk in elderly patients with dementia-related psychosis 9
• The evidence for aripiprazole in anxiety comes from augmentation studies in treatment-resistant cases, not as monotherapy 7, 8
• Most aripiprazole anxiety data is from retrospective reviews and small open-label trials, not rigorous RCTs 6, 9
• Lamotrigine's use in anxiety lacks any substantial evidence base and recent guidelines recommend against it 2

Bottom line: If you must choose between these two for treatment-resistant anxiety after SSRI failure, aripiprazole has marginally more supporting evidence as augmentation therapy, while lamotrigine should be avoided for this indication.